feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

Doomsday Glacier nearing collapse

trending

Los Angeles flash flood warning

trending

GDP boosts stock market

trending

Severe thunderstorm warning issued

trending

Gold, silver prices surge

trending

William Rush dead at 31

trending

Ernest Heinz indicted for shooting

trending

AWS focuses on AI agents

trending

Tim Cook buys Nike stock

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Veterinary Sedative Fuels New Opioid Epidemic Nightmare

Veterinary Sedative Fuels New Opioid Epidemic Nightmare

15 Dec

•

Summary

  • Medetomidine, a vet sedative, causes severe withdrawal, overwhelming hospitals.
  • Drug supply in Philadelphia sees 91% fentanyl mix with medetomidine.
  • Hospital admissions for withdrawal surged over 160% in nine months.
Veterinary Sedative Fuels New Opioid Epidemic Nightmare

Philadelphia is grappling with a new drug crisis fueled by medetomidine, a potent veterinary sedative. This drug, now found in 91% of the city's fentanyl supply, causes severe and life-threatening withdrawal symptoms, including dangerously high blood pressure and heart rates, overwhelming local hospitals.

The consequences are dire, with hospital admissions for medetomidine withdrawal soaring by over 160% in the first nine months of 2025 compared to all of 2023. This situation strains emergency services and has led to intensive care units being overburdened, creating a distinct "withdrawal crisis."

Medetomidine's addictive nature and low cost make it attractive to drug dealers, and its impact is spreading to other states. The crisis highlights the evolving challenges of addiction, with withdrawal, not overdose, becoming the primary threat.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Medetomidine is a powerful veterinary sedative, not intended for human use, that has entered Philadelphia's drug supply. It causes severe withdrawal symptoms that are overwhelming hospitals.
Hospitals in Philadelphia have been strained by a surge in patients experiencing medetomidine withdrawal, leading to ICU overcrowding and an increase in critical care needs.
Withdrawal from medetomidine can cause catastrophically high heart rates and blood pressure, tremors, uncontrollable vomiting, and in severe cases, require intensive care.

Read more news on

Healthside-arrow

You may also like

New Drug Overwhelms Pittsburgh ERs with Violent Patients

1 day ago • 17 reads

article image

Rhino Tranq: The New Drug Causing Organ Failure

1 day ago • 6 reads

article image

Ozempic Effect: Restaurants Serve Mini-Meals

1 day ago • 9 reads

article image

FDA Proposes Catch-Up for US Sunscreen Standards

12 Dec • 79 reads

article image

Belfast Man's Painkiller Addiction Leads to Surgery

8 Dec • 104 reads

article image